Keyphrases
Active Joint
33%
Activity Groups
25%
Anti-drug Antibodies
33%
Axial Spondyloarthritis (AxSpA)
42%
Biological Disease-modifying Antirheumatic Drugs (bDMARDs)
25%
Clinical Practice
33%
Clinical Significance
33%
Clinically Inactive Disease
25%
Comorbidity
33%
Cut-off Level
16%
Disease Activity
30%
Disease-modifying Antirheumatic Drugs (DMARDs)
76%
Drug Sales
18%
Drug Therapy
33%
Early Rheumatoid Arthritis
40%
Early Spondyloarthritis
33%
Erosive Disease
33%
Finland
73%
First Year
33%
Frequency of Use
33%
Hydroxychloroquine
18%
Immunogenicity
33%
Infliximab
33%
Joint Counts
33%
Low Disease Activity
25%
Malignancy
33%
Methotrexate
29%
Nationwide Registers
33%
New Onset
41%
Newly Diagnosed
33%
Opioid Consumption
25%
Opioid Use
33%
Opioids
25%
Population Control
28%
Quality Register
33%
Real-life Setting
41%
Register Study
66%
Resistin
33%
Resistin Levels
33%
Rheumatoid Arthritis
38%
Rheumatology
33%
Social Insurance
17%
Spondyloarthritis
33%
Subcutaneous Tumor
33%
Systemic Lupus Erythematosus
60%
Systemic Lupus Erythematosus Patient
74%
Trough Level
28%
Tumor Necrosis Factor-α
33%
Tumour Necrosis Factor Inhibitor (TNFi)
33%
Undifferentiated Arthritis
33%
Pharmacology, Toxicology and Pharmaceutical Science
Arthritis
33%
Biological Product
22%
Cohort Study
11%
Combination Drug
18%
Combination Therapy
11%
Congenital Malformation
6%
Defined Daily Dose
7%
Disease
33%
Disease Activity
26%
Disease Modifying Antirheumatic Drug
66%
Drug Antibody
33%
Drug Concentration
9%
Hydroxychloroquine
20%
Immunogenicity
33%
Inflammation
7%
Inflammatory Arthritis
66%
Infliximab
33%
Methotrexate
46%
Opiate
33%
Pharmacotherapy
33%
Prednisolone
14%
Preeclampsia
6%
Resistin
33%
Rheumatoid Arthritis
66%
Spondylarthritis
66%
Sulfasalazine
19%
Systemic Lupus Erythematosus
33%
Trough Level
28%
Tumor Necrosis
14%
Tumor Necrosis Factor
33%
Tumor Necrosis Factor Inhibitor
33%
Medicine and Dentistry
Cancer
33%
Combination Drug
7%
Congenital Malformation
6%
Disease
69%
Disease Activity
40%
Disease Activity Score
10%
Disease Modifying Antirheumatic Drug
33%
Erythrocyte Sedimentation Rate
6%
Hydroxychloroquine
9%
Inflammatory Arthritis
33%
Infliximab
33%
Juvenile Idiopathic Arthritis
6%
Macrophage
7%
Multiple Chronic Conditions
33%
Patient-Data
6%
Population Dynamics
15%
Pre-Eclampsia
6%
Resistin
33%
Rheumatoid Arthritis
33%
Rheumatology
33%
Systemic Juvenile Idiopathic Arthritis
6%
Systemic Lupus Erythematosus
100%
Tumor Necrosis
14%